If the observed increases in intratumoral CD8(+) cells and PD-L1 expression with S-588410 occur in patients with urothelial carcinoma, combination therapy with S-588410 and an anti-PD-L1 antibody may offer an effective treatment option. Here, CD8A is linked to urothelial carcinoma.